Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy amid a Senate probe into what the company charges.
Speaking on an earnings call Thursday, Chief Executive Lars Fruergaard Jørgensen said the company launched the treatments at similar prices to earlier generations in the drug class, despite having greater efficacy, making them “an attractive value proposition.”
He added that while the large number of people taking the treatments “is to some degree putting strains on health care systems,” the full value of Ozempic and Wegovy has not yet been realized, since the drugs over time are treating and preventing chronic conditions that are currently burdening health systems.
Click this link for the original source of this article.
Author: Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.